The Dadachanji Group, whose promoters built pharmaceutical glass-packaging company Schott Kaisha before exiting the venture in 2021, has launched KAISHA Pharma, marking its return to the segment with an initial investment of €45 million as it targets Indian and global pharmaceutical and biotechnology companies.

The company plans to build KAISHA Pharma as a global healthcare platform, with the investment aimed at developing its pharmaceutical operations, strengthening manufacturing capabilities and expanding its presence across international markets.

KAISHA Pharma will focus on developing and commercialising pharmaceutical products, with the company expected to leverage the Dadachanji Group’s business network and resources to establish a presence in key healthcare markets.

The company is setting up a manufacturing complex spread over more than 300,000 square feet, equipped with integrated production lines, camera-based inspection systems, and analytical and testing laboratories.

KAISHA Pharma will manufacture primary pharmaceutical packaging products, including ampoules, vials, prefilled syringes and cartridges, along with ready-to-use (RTU) platforms for vials, syringes and cartridges.

The company is also developing specialty containment solutions for biologics, advanced therapeutics and sensitive drug formulations.

KAISHA Pharma is setting up an international business development office in Europe, which will serve as a hub for customer engagement, technical collaboration and market development in the region.